Author

Yongchuan Gu

Observed names: Gu, Yongchuan, Y GU, Y. C. Gu, Y. Gu, Yuzhuo Gu

Institutions: University of Auckland, Monash University

Observed institutions: Lawrence Livermore National Laboratory, University of Auckland, China Pharmaceutical University, Yanbian University, Wuxi Municipal Product Quality Supervision and Inspection Institute, Maurice Wilkins Centre, Stanford Medicine, Ontario Veterinary College, Monash University, Zhejiang University, University of Guelph, University of Otago, Beihang University, Stanford University

ORCID: 0000-0001-5679-168X

Observed ORCID: 0000-0001-5679-168X

OpenAlex ID: A5041236682

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

2007 · Adam V. Patterson, Dianne M. Ferry, et al. · Clinical Cancer Research · 253

PDF

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

2015 · M. Konopleva, P. F. Thall, et al. · Haematologica · 124

PDF

Transport and Bioavailability Studies of Astragaloside IV, an Active Ingredient in Radix Astragali

2004 · Yongchuan Gu, Guangji Wang, et al. · Basic & Clinical Pharmacology & Toxicology · 95

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

2015 · Francis W. Hunter, Richard J. Young, et al. · Cancer Research · 83

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

2011 · Mark J McKeage, Yongchuan Gu, et al. · BMC Cancer · 77

PDF

Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells

2015 · Ji Cao, Yijie Wang, et al. · Cancer Research · 75

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides

2017 · Muriel Bonnet, Cho Rong Hong, et al. · Journal of Medicinal Chemistry · 71

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

2009 · Yongchuan Gu, Adam V. Patterson, et al. · Molecular Cancer Therapeutics · 69

PDF

Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells

2008 · James W. Evans, Sophia B. Chernikova, et al. · Cancer Research · 69

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

2012 · Mark J McKeage, Michael B Jameson, et al. · BMC Cancer · 68

PDF

Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma

2005 · Y GU, J FAWCETT · Journal of Chromatography B · 55

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1

2014 · Guanyu Lin, Renhua Gai, et al. · European Journal of Pharmacology · 48

Selective Treatment of Hypoxic Tumor Cells In Vivo: Phosphate Pre‐Prodrugs of Nitro Analogues of the Duocarmycins

2011 · Moana Tercel, Graham J. Atwell, et al. · Angewandte Chemie International Edition · 46

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

2014 · Stephen M.F. Jamieson, Yongchuan Gu, et al. · Biochemical Pharmacology · 42

Determination of Astragaloside IV in rat plasma by liquid chromatography electrospray ionization mass spectrometry

2004 · Yongchuan Gu, Guangji Wang, et al. · Journal of Chromatography B · 42

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

2015 · Maria R Abbattista, Stephen M F Jamieson, et al. · Cancer Biology & Therapy · 36

PDF

Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

2010 · Peter J. Houghton, Richard Lock, et al. · Pediatric Blood & Cancer · 33

Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography–mass spectrometry

2007 · Kashyap Patel, David Lewiston, et al. · Journal of Chromatography B · 29

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361

2019 · Way Wua Wong, Rosanna K. Jackson, et al. · Biochemical Pharmacology · 28

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs

2014 · Francis W. Hunter, Jagdish K. Jaiswal, et al. · Biochemical Pharmacology · 26

The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer

2020 · Hong Zhu, Yan Hu, et al. · Theranostics · 25

PDF

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence

2013 · Jiechuang Su, Yongchuan Gu, et al. · Journal of Biological Chemistry · 25

PDF

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers

2014 · Muriel Bonnet, Cho Rong Hong, et al. · Bioorganic & Medicinal Chemistry · 23

Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy

2011 · Yongchuan Gu, Malcolm D. Tingle, et al. · Journal of Pharmacology and Experimental Therapeutics · 23

Rapid and sensitive ultra-high-pressure liquid chromatography–tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study

2009 · Yongchuan Gu, William R. Wilson · Journal of Chromatography B · 23

Works count: 93

Citation count: 1,655

H-index: 23

I10-index: 32